What Tenpoint Therapeutics does

Tenpoint Therapeutics is a privately held, venture-backed ophthalmic biopharmaceutical company formed in its current form through the December 2024 merger of Tenpoint Therapeutics and Visus Therapeutics. The company is dual-headquartered, with a US operating entity in Warren, NJ and a UK parent (Tenpoint Therapeutics Holding Limited) registered in Camborne, England, employing 11-50 people across England, Switzerland and the United States. Its mission is to develop vision-restoring therapeutics for age-related eye conditions, anchored by a single FDA-approved commercial asset and a small preclinical pipeline.

YUVEZZI (carbachol 2.75% + brimonidine tartrate 0.1% ophthalmic solution) is the company's lead and only FDA-approved product: a once-daily dual-agent eye drop that combines a long-acting miotic with an alpha-2 adrenergic agonist to produce a pinhole effect for near-vision improvement in adults with presbyopia, supported by Phase 3 data from the BRIO-I and BRIO-II trials across more than 800 patients. The pipeline adds two preclinical assets: TPT-161, a multi-targeted NCE combining an alpha-crystallin chaperone with a reducing agent for dysfunctional lens syndrome (presbyopia/cataract), and TPT-005, an allogeneic hESC-derived RPE cell therapy delivered via subretinal injection for geographic atrophy.

The company makes money by selling YUVEZZI as a prescription eye drop through U.S. retail and e-pharmacies following its March 2026 nationwide launch, supplemented by a direct-to-patient cash program in partnership with PHIL Inc. priced at $198 for 90 days of therapy. Customers are fragmented across the approximately 128 million U.S. adults with presbyopia, reached via a specialty pharma field-sales channel targeting ophthalmologists and optometrists, with manufacturing outsourced to Ritedose Corporation under a sterile Blow-Fill-Seal contract. Revenue is supported by $235 million of capital raised in January 2026 ($85M Series B equity plus $150M senior secured debt from Hercules Capital) to fund U.S. commercialization and pipeline progression.

Name

Tenpoint Therapeutics

Legal name

Tenpoint Therapeutics Ltd.

Website

https://tenpointtherapeutics.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

101–250 employees

Short description

Tenpoint Therapeutics is a privately held ophthalmic biopharmaceutical company that develops vision-restoring therapeutics for age-related eye conditions, anchored by YUVEZZI, a FDA-approved once-daily dual-agent eye drop for presbyopia, plus preclinical assets targeting cataracts and geographic atrophy, sold to eye care professionals and adult patients across the U.S. and selectively in South Korea.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)

SIC

Surgical & Medical Instruments & Apparatus (3841), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Pharmaceuticals (HLAIAAAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Ophthalmic therapeutics
• Presbyopia treatment
• Prescription eye drops
• Biotechnology pharmaceuticals
• Vision restoration

Headquarters

HQ city

Camborne

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. YUVEZZI prescription drug sales: Primary revenue driver is the commercial sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution 2.75% / 0.1%), the first and only FDA-approved dual-agent eye drop for presbyopia in adults. Sold as a once-daily prescription through retail and e-pharmacies across the United States following the January 28, 2026 FDA approval and late March 2026 nationwide launch.
2. Direct-to-patient cash program (with PHIL Inc.): Out-of-pocket cash-pay channel operated with PHIL Inc. offering transparent pricing, home delivery, and dedicated support. Pricing disclosed at $198 for 90 days of therapy, providing an alternative to insurance reimbursement and addressing access barriers for the approximately 128 million Americans affected by presbyopia.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Tenpoint Therapeutics develops and commercializes prescription ophthalmic therapeutics for age-related vision loss, with YUVEZZI — the first and only FDA-approved dual-agent eye drop combining carbachol 2.75% and brimonidine tartrate 0.1% — as its lead commercial asset for adults with presbyopia. The company is also advancing two preclinical pipeline assets: TPT-161, an alpha-crystallin chaperone-based small molecule for cataracts and dysfunctional lens syndrome, and TPT-005, an allogeneic hESC-derived RPE cell therapy for geographic atrophy.

Product overview

Tenpoint Therapeutics operates a focused single-therapeutic-area biopharmaceutical portfolio built around vision restoration for the aging eye, organized as a lead commercial asset plus a small preclinical pipeline rather than a platform-plus-modules software architecture. Its sole FDA-approved product, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%; known in clinical trials as BRIMOCHOL™ PF), is a dual-agent once-daily eye drop for presbyopia and is supported by patient-facing (yuvezzi.com) and eye-care-professional-facing (yuvezziecp.com) properties. The pipeline consists of two preclinical investigational programs: TPT-161, a small-molecule alpha-crystallin chaperone + reducing agent NCE targeting presbyopia/cataracts within dysfunctional lens syndrome, and TPT-005, an allogeneic hESC-derived RPE cell therapy for geographic atrophy (advanced dry AMD).

Differentiator

Problem solved

Functional benefit

Brands

• YUVEZZI: FDA-approved (January 28, 2026) once-daily dual-agent ophthalmic solution combining carbachol 2.75% and brimonidine tartrate 0.1% for the treatment of presbyopia in adults; first and only FDA-approved combination eye drop for this indication. Commercial launch in the United States occurred in March 2026.
• BRIMOCHOL PF
• TPT-161
• TPT-005
• Yuvezzi / YuvezziECP

Products and services

• YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1% Once-daily prescription eye drop for adults with presbyopia; combines carbachol (a long-acting miotic that constricts the pupil) with brimonidine tartrate (an alpha-2 adrenergic agonist that prevents pupil dilation) to produce a pinhole effect that sharpens near vision. FDA-approved on January 28, 2026 as the first and only combination eye drop for presbyopia in adults; previously known in clinical trials as BRIMOCHOL PF. Available through retail and e-pharmacies and via a $198/90-day direct-to-patient cash program with PHIL Inc.
• TPT-161 Investigational multi-targeted new chemical entity combining an alpha-crystallin chaperone with a reducing agent; designed to disrupt the Dysfunctional Lens Syndrome continuum by stabilizing lens proteins, breaking protein bonds, reversing lens protein aggregation, and restoring lens flexibility and clarity via a non-surgical approach for presbyopia and cataract patients. Currently in preclinical development.
• TPT-005 Investigational allogeneic regenerative cell therapy containing fully differentiated retinal pigment epithelium (RPE) cells derived from human embryonic stem cells (hESC); delivered via subretinal injection as a ready-to-use, off-the-shelf injectable designed to replace lost RPE cells in advanced dry AMD (geographic atrophy). Currently in preclinical development.

Quantifiable outcome

• YUVEZZI is the first and only FDA-approved dual-agent eye drop for presbyopia in adults (January 28, 2026 approval)
• +6 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core, minor and flagship.

• Ritedose CorporationcoreOthers · 8 April 2026Ritedose Corporation, a U.S. contract development manufacturing organization specializing in sterile Blow-Fill-Seal production with over 25 years of experience in sterile ophthalmic manufacturing, partnered with Tenpoint Therapeutics to manufacture YUVEZZI (the first and only FDA-approved dual-agent eye drop for presbyopia). The partnership is intended to de-risk production and ensure supply security for the launch.
• PHIL Inc.coreGTM or Marketing Partner · 2 April 2026Tenpoint Therapeutics Ltd and PHIL Inc. launched a Direct-to-Patient cash program for YUVEZZI to make the novel presbyopia therapy more accessible and affordable. The program offers transparent pricing ($198 for 90 days), home delivery, and dedicated support, addressing high out-of-pocket costs and access barriers for adults with presbyopia.
• Goodwin Procter LLPminorImplementation/ SI/ Consulting Partner · 6 February 2026Goodwin advised Tenpoint Therapeutics on its $235 million Series B financing and credit facility transaction announced in late January 2026. Role was as legal counsel to the company.
• Visus Therapeutics, Inc.flagshipStrategic or Co-development Partner · 12 December 2024Tenpoint Therapeutics and Visus Therapeutics merged on December 12, 2024 to form a new company focused on ophthalmic medicines, combining pipelines and accelerating development of presbyopia-correcting eye drops and other age-related eye condition therapies. The merger included a crossover financing round with key venture investors. Visus Therapeutics, Inc. is now an affiliate of Tenpoint Therapeutics, Ltd. and is the originator and trademark holder of YUVEZZI.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lenz Therapeutics: Lenz Therapeutics is developing aceclidine-based presbyopia eye drops (e.g., LNZ100/101), the most direct mechanistic competitor to Tenpoint's YUVEZZI, targeting the same ophthalmologist/optometrist channel and similar patient population.
• Orasis Pharmaceuticals: Orasis developed Qlosi (pilocarpine ophthalmic solution) for presbyopia, another miotic-based eye drop approved to treat the same indication as YUVEZZI using a closely comparable mechanism and prescriber audience.

Broad incumbents

• AbbVie / Allergan Aesthetics: AbbVie markets Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop, and competes directly with YUVEZZI via the same ophthalmology/optometry channel while also offering a broad eye care and aesthetics portfolio.
• Alcon: Alcon is the largest dedicated ophthalmic device and pharmaceutical company globally, with broad portfolios in surgical, vision care, and pharmaceuticals (including dry eye and retina) that overlap Tenpoint's presbyopia and future geographic atrophy ambitions.
• Bausch + Lomb: Bausch + Lomb is a diversified eye care incumbent with pharmaceutical, surgical, and consumer vision care franchises (including reading glasses and dry eye products), making it both a competitor and a potential strategic acquirer for a presbyopia-focused company like Tenpoint.
• Apellis Pharmaceuticals: Apellis markets Syfovre (pegcetacoplan), the first FDA-approved therapy for geographic atrophy, directly overlapping with Tenpoint's preclinical TPT-005 program and shaping the competitive context for any AMD pipeline asset.
• Astellas / Iveric Bio: Astellas (via acquired Iveric Bio) markets Izervay (avacincaptad pegol) for geographic atrophy, a second approved complement inhibitor competing in the same indication targeted by Tenpoint's TPT-005 RPE cell therapy.
• Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept) for wet AMD and is expanding into geographic atrophy via Eylea HD, representing a large incumbent R&D and commercial competitor in the AMD space where Tenpoint's TPT-005 is positioned.

Emerging players

• Eyenovia: Eyenovia is developing MicroLine (pilocarpine microdose array print delivery) for presbyopia, an emerging alternative delivery approach targeting the same presbyopia patient population addressed by YUVEZZI.
• Lineage Cell Therapeutics: Lineage is developing allogeneic retinal pigment epithelium cell therapies (e.g., OpRegen for geographic atrophy), the closest direct cell-therapy peer to Tenpoint's hESC-derived TPT-005 for the same advanced dry AMD indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Customer concentration

• LinkedInlinkedin.com/company/tenpoint-therapeutics
• Instagraminstagram.com/tenpointtherapeutics
• Xx.com/tenpointtx

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tenpoint Therapeutics